TRIBUTE comic book series celebrates rapper DMX. PHOTO COURTESY OF TIDALWAVE COMICS TidalWave Comics announces the addition ...

We recently compiled a list of the 7 Most Promising Gene Editing Stocks According to Analysts. BioMarin Pharmaceuticals Inc.

The Amicus acquisition will bolster BioMarin’s rare disease portfolio, while potentially growing the company’s future revenue ...

BMRN agrees to acquire FOLD for $4.8B, adding two growing rare disease drugs and a late-stage pipeline asset to its portfolio.

BioMarin Pharmaceutical said on Friday it would acquire Amicus Therapeutics for about $4.8 billion, in the drugmaker's second deal this year to expand its presence in rare diseases.

Amid news of the splashy $4.8 billion Amicus buy, BioMarin has slipped in the discontinuation of a genetic liver disease ...

In a merger of rare disease specialists, BioMarin has agreed to acquire Amicus Therapeutics for $4.8 billion. The California ...

Biomarin Pharmaceutical Inc. is paying $14.50 per share to acquire rare disease drug developer Amicus Therapeutics Inc. in an all-cash transaction valued at about $4.8 billion. The deal will bolster ...

BioMarin Pharmaceutical has faced a rocky road, promising and then backing off revenue targets and cutting assets that have underperformed. But Amicus’ rare disease portfolio is already bringing in ...

The Biotech Growth Trust PLC - BioMarin Pharmaceuticals to acquire BIOG portfolio company, Amicus Therapeutics ...

TidalWave Comics has announce the addition of iconic rapper DMX to its acclaimed TRIBUTE comic book series, which celebrates ...

BioMarin Pharmaceutical ( ($BMRN) ) has shared an update. On December 19, 2025, BioMarin Pharmaceutical agreed to acquire Amicus Therapeutics in ...